Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data

Anixa Biosciences (Nasdaq: ANIX) is advancing a clinical-stage oncology pipeline focused on cancer vaccines and CAR-T therapy, led by its breast cancer vaccine program developed with Cleveland Clinic and supported by U.S. Department of Defense funding.In our exclusive interview, Dr. Amit Kumar, Chairman & CEO of Anixa Biosciences, discusses the company’s breast cancer vaccine targeting alpha-lactalbumin, its completed Phase 1 study, the path toward Phase 2, and the long-term vision of potentially preventing breast cancer before it starts. Dr. Kumar also highlights Anixa’s ovarian cancer CAR-T program, where early clinical data has shown extended survival in certain heavily pretreated patients.Why investors are watching ANIX:• Breast cancer vaccine Phase 1 completed with no major safety concerns reported• 74% protocol-specified immune response reported in Anixa’s investor deck• Phase 2 breast cancer vaccine enrollment listed as an upcoming milestone• Ovarian cancer CAR-T program provides a second clinical-stage opportunity• $14M in cash and short-term investments, no debt, and a clean capital table as of January 31, 2026• Partnerships include Cleveland Clinic, The Wistar Institute, and U.S. Department of Defense supportLearn more about Anixa Biosciences: https://www.redchip.com/stocks/ANIX#ANIX #AnixaBiosciences #BiotechStocks #CancerVaccine #BreastCancer #CART #Oncology #SmallCapStocks #NASDAQ #InvestorInterview #RedChip